LifeStance Health Group (LFST) Stock Looks Strong On Returns Yet Stretched On Earnings
LifeStance Health Group stock has delivered a sharp 146.8% return over the past year, yet its valuation checks still flag the shares as expensive rather than a clear bargain. For investors looking at LifeStance Health Group today, the recent gains sit alongside a low value score and a market view that the stock trades on rich multiples.
- LifeStance Health Group has returned 146.8% over the past 12 months, which means anyone stepping in now is doing so after a strong run.
- Stronger revenue, profitability and a new share repurchase program can support higher expectations for the business, while any disappointment in future growth or margins may quickly pressure what investors are willing to pay for the stock.
- On Simply Wall St's broader valuation checks, LifeStance Health Group is assessed as expensive on all measures, with a low value score of 0 out of 6. This points to limited evidence of obvious undervaluation.
The issue now is whether LifeStance Health Group's current share price still offers enough value after this strong run or whether expectations built into the stock have moved too far ahead of the fundamentals.
Has LifeStance Health Group Run Too Far on Earnings?
The P/E ratio is the main focus for LifeStance Health Group because the company is now reporting positive net income that can anchor an earnings based comparison. LifeStance Health Group currently trades on a P/E of 86.8x, which sits well above the broader Healthcare industry average of 24.7x and also above the peer group average of 70.8x. That already puts the stock at a clear premium to many other healthcare providers on simple earnings terms.
On Simply Wall St’s tailored fair multiple, which blends factors such as growth profile, margins, size and risk, LifeStance Health Group screens on a fair P/E closer to 42.8x. The gap between this figure and the current 86.8x indicates that the stock valuation embeds a substantial amount of positive expectations. Despite LifeStance recently reporting strong quarterly results and raising its 2026 outlook, the current P/E still sits well ahead of what this framework points to as a more grounded level.
Overall, LifeStance Health Group appears expensive on its current P/E multiple compared with both tailored and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The LifeStance Health Group Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the LifeStance Health Group valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, based on views shared on the Community page. Each narrative links its number to a specific view on how LifeStance Health Group's growth, profitability and risks might evolve, which you can revisit as new data arrives.
Community views on LifeStance Health Group now sit on two very different tracks, with one camp leaning into the upside story and the other focused on the risks around execution and competition.
Bull case: 12% undervalued
"LifeStance's increasingly differentiated clinician support platform, industry-leading documentation automation, and robust cash-based incentive programs position it to command outsized clinician net adds and sharply lower churn..."
Read the full Bull Case to see why LifeStance Health Group could be undervalued
Bear case: 28% overvalued
"Increased competition from digital and integrated health providers, alongside clinician turnover, threatens growth in patient volume, market share, and margins..."
Read the full Bear Case to see why LifeStance Health Group could be overvalued
Do you think there's more to the story for LifeStance Health Group? Head over to our Community to see what others are saying!
The Bottom Line
LifeStance Health Group screens as overvalued on market multiples, with the current P/E sitting well above both industry and tailored fair multiple benchmarks. That leaves less room for error if growth or margin progress falls short of what the price implies. The key question from here is whether LifeStance Health Group can deliver a level of sustainable earnings expansion that keeps investors comfortable paying this kind of premium, or whether the multiple eventually settles closer to peers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com